SCHEMBL25475446

SCHEMBL25475446

CCOC(=O)[C@@H]1C[C@H]2C/C(=C/Cc3nnn[nH]3)CC[C@H]2CN1C(=O)OCc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.35
TMEM97 Q5BJF2 4/20 0.34
SIGMAR1 Q99720 4/20 0.34
ELANE P08246 1/20 0.34
ACE P12821 2/20 0.33
TSHR P16473 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
HTR1A P08908 1/20 0.33
CHRM5 P08912 1/20 0.33
SLC6A2 P23975 1/20 0.33
HRH2 P25021 1/20 0.33
ADRA1D P25100 1/20 0.33
HTR1B P28222 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR1E P28566 1/20 0.33
HRH1 P35367 1/20 0.33
HTR2B P41595 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24165707 0.86 UCHL1 (0.30)
SCHEMBL30332495 0.86 UCHL1 (0.30)
SCHEMBL25475449 0.79 POLB (0.34) POLBTMEM97SIGMAR1ACETSHR
SCHEMBL25475443 0.78 POLB (0.43) POLBELANETSHRL3MBTL1KDM4E
SCHEMBL26197074 0.78 POLB (0.43) POLBELANETSHRL3MBTL1KDM4E
SCHEMBL24165705 0.78 POLB (0.43) POLBELANETSHRL3MBTL1KDM4E
SCHEMBL30332355 0.78
SCHEMBL26197145 0.78 POLB (0.37) POLBTMEM97SIGMAR1ELANETSHR
SCHEMBL24166272 0.78
SCHEMBL6604771 0.77 FKBP1A (0.39) POLBACETSHRL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4175635-B1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF SEA PHARMACEUTICALS LLC (US) 2026-03-25 EP disclosed
US-20250074887-A1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF Sea Pharmaceuticals LLC. (US) 2025-03-06 US disclosed
WO-2023130008-A2 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF SEA PHARMACEUTICALS LLC (US) 2023-07-06 WO disclosed
US-11685726-B2 Pharmaceutical compositions of 6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and ester derivatives thereof SEA PHARMACEUTICALS LLC (US) 2023-06-27 US disclosed
US-11685726-B2 Pharmaceutical compositions of 6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and ester derivatives thereof SEA PHARMACEUTICALS LLC (US) 2023-06-27 US disclosed
US-11685726-B2 Pharmaceutical compositions of 6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and ester derivatives thereof SEA PHARMACEUTICALS LLC (US) 2023-06-27 US disclosed
US-20230150971-A1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF SEA PHARMACEUTICALS LLC (US) 2023-05-18 US disclosed
US-20230150971-A1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF SEA PHARMACEUTICALS LLC (US) 2023-05-18 US disclosed
US-20230150971-A1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF SEA PHARMACEUTICALS LLC (US) 2023-05-18 US disclosed
EP-4175635-A1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF Sea Pharmaceuticals LLC (US) 2023-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074887-A1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF GABRQ, GRIK5, CYP3A7 POLB 4272/4885TMEM97 1871/4885SIGMAR1 3731/4885
US-11685726-B2 Pharmaceutical compositions of 6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and ester derivatives thereof KCNQ5, KCNQ2, KCNQ3 POLB 4509/4885TMEM97 1492/4885SIGMAR1 1462/4885
US-20230150971-A1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF KCNQ5, KCNQ2, KCNQ3 POLB 4509/4885TMEM97 1492/4885SIGMAR1 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.